Measles/Rubella
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
TakedaTOKYO, Japan
1 programFreeze-dried live attenuated measles and rubella combined vaccineN/AVaccine2 trials
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
TakedaFreeze-dried live attenuated measles and rubella combined vaccine
TakedaFreeze-dried live attenuated measles and rubella combined vaccine
Clinical Trials (2)
Total enrollment: 6,824 patients across 2 trials
Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
Start: Mar 2007Est. completion: Feb 20113,331 patients
N/ACompleted
Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination
Start: Feb 2006Est. completion: Apr 20093,493 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space